A new mouse line with reduced GluA2 Q/R site RNA editing exhibits loss of dendritic spines, hippocampal CA1-neuron loss, learning and memory impairments and NMDA receptor-independent seizure vulnerability

Lyndsey M. Konen\(^1,2\)^†, Amanda L. Wright\(^3\), Gordon A. Royle\(^4,5\)^†, Gary P. Morris\(^1,2\)^†, Benjamin K. Lau\(^6\)^†, Patrick W. Seow\(^6\), Raphael Zinn\(^1,2\), Luke T. Milham\(^1,2\), Christopher W. Vaughan\(^6\) and Bryce Vissel\(^1,2\)*

Abstract

Calcium (Ca\(^{2+}\))-permeable AMPA receptors may, in certain circumstances, contribute to normal synaptic plasticity or to neurodegeneration. AMPA receptors are Ca\(^{2+}\)-permeable if they lack the GluA2 subunit or if GluA2 is unedited at a single nucleic acid, known as the Q/R site. In this study, we examined mice engineered with a point mutation in the intronic editing complementary sequence (ECS) of the GluA2 gene, Gria2. Mice heterozygous for the ECS mutation (named GluA2\(^+/-\)ECS(G)) had a ~20% reduction in GluA2 RNA editing at the Q/R site. We conducted an initial phenotypic analysis of these mice, finding altered current-voltage relations (confirming expression of Ca\(^{2+}\)-permeable AMPA receptors at the synapse). Anatomically, we observed a loss of hippocampal CA1 neurons, altered dendritic morphology and reductions in CA1 pyramidal cell spine density. Behaviourally, GluA2\(^+/-\)ECS(G) mice exhibited reduced motor coordination, and learning and memory impairments. Notably, the mice also exhibited both NMDA receptor-independent long-term potentiation (LTP) and vulnerability to NMDA receptor-independent seizures. These NMDA receptor-independent seizures were rescued by the Ca\(^{2+}\)-permeable AMPA receptor antagonist IEM-1460. In summary, unedited GluA2(Q) may have the potential to drive NMDA receptor-independent processes in brain function and disease. Our study provides an initial characterisation of a new mouse model for studying the role of unedited GluA2(Q), synapse loss, neurodegeneration, behavioural impairments and/or seizures are observed, such as ischemia, seizures and epilepsy, Huntington’s disease, amyotrophic lateral sclerosis, astrocytoma, cocaine seeking behaviour and Alzheimer’s disease.

Keywords: GluA2, AMPA receptors, RNA editing, Hippocampus, Seizures, Neurodegeneration, Alzheimer’s disease, Long term potentiation, Synapses
**Introduction**

Within the central nervous system (CNS), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) mediate the majority of fast excitatory neurotransmission [1]. AMPARs are tetrameric protein complexes composed of differing combinations of four subunits, denoted GluA1-GluA4 (also known as GluR1–4 and GluRA-D, for a full review of AMPAR architecture refer here [2]). Diversity of AMPARs is created through several mechanisms including differing subunit composition [3–6], posttranslational modifications [7, 8], alternative splicing [9] and a process known as RNA editing [10–12], all of which can profoundly alter AMPAR properties.

RNA editing at the Q/R site (position 607) of GluA2 is a crucial editing event occurring in AMPAR subunits [10, 13, 14]. At this site, an adenosine to inosine (A-to-I) editing event results in an exonically encoded CAG codon being edited to a CIG in the pre-mRNA [14]. The CIG codon is read as a CGG because the inosine, in most cases, is interpreted as a G during translation [15], resulting in a conversion of glutamine (CAG, i.e. Q) to an arginine (CGG, i.e. R). The editing-induced amino acid change has a profound impact: AMPARs containing edited GluA2[R] (which appear to constitute a majority of total AMPARs physiologically [4–6, 16]) are Ca²⁺-impermeable. This likely occurs because the arginine is positively charged and present in the pore-lining (M2) region [17] which, in contrast to the uncharged glutamine, prevents Ca²⁺ flux. Alternatively, AMPARs that lack the GluA2 subunit (i.e. that are assembled from homomeric or heteromeric combinations of GluA1, A3 and A4), or that contain unedited GluA2[Q], are Ca²⁺-permeable [10, 18–22].

It is unclear why this GluA2 editing process has evolved [23–25], especially considering GluA2 Q/R site editing is ~ 99% efficient in the healthy adult brain. However, it is highly conserved [26, 27], hinting at a strong selective pressure for retaining the editing process [25, 28]. Although forced-edited mice expressing only GluA2[R] appear normal [23], suggesting unedited GluA2[Q] is not required for normal brain development and function, we have previously argued that unedited GluA2[Q] may have unrecognised physiological roles when present in mature AMPARs [10]. Furthermore, a decrease in editing efficiency has been observed in several human neurological conditions including Alzheimer’s disease [29–31], schizophrenia [30], Huntington’s disease [30], amyotrophic lateral sclerosis [32], astrocytoma [33], ischemia [34] as well as cocaine seeking behaviour in rats [35] (for a review see [36]). These findings suggest a decrease in GluA2 Q/R site editing efficiency (leading to increased proportions of unedited GluA2[Q] subunits, relative to edited GluA2[R]), may play a role in the aetiology of these conditions.

Supporting this hypothesis, several seminal studies have described the phenotype of mice with forced expression of varying levels of unedited GluA2(Q). In these studies, mice were genetically engineered with deletions of the Gria2 intronic editing complimentary sequence (ECS) that is necessary for Q/R site RNA editing [37–39]. The mice exhibited severely compromised phenotypes including a propensity for seizures, premature mortality, synaptic transmission abnormalities and hippocampal cell death [37–39] (also see a study in zebrafish [40]). The seizures and premature mortality are reminiscent of adenosine deaminase acting on RNA 2 (ADAR2) knockout (KO) mice (ADAR2 is the enzyme responsible for editing GluA2 [41]). ADAR2 KO mice have a higher proportion of unedited GluA2(Q) compared with edited GluA2(R) and their phenotype can be significantly improved by the forced expression of edited GluA2(R), suggesting unedited GluA2(Q) is the primary driver of ADAR2 KO mouse abnormalities [28, 42]. Furthermore, the expression of unedited GluA2(Q) in adult mice renders hippocampal neurons more vulnerable to ischemic insult [34, 43, 44].

Collectively, these studies hint to possible roles for unedited GluA2(Q) in the aetiology of several neurological conditions, but there is much yet to learn and further studies are needed. In particular, the phenotype of mice genetically engineered to express higher proportions of unedited GluA2(Q) has not yet been fully characterised, in part because of the reduced lifespan of prior models, leading to a lack of understanding of the role of unedited GluA2(Q) in vivo. In this study we therefore generated a new mouse line with a single point mutation in the ECS that was previously found in vitro to regulate GluA2 Q/R site RNA editing [45]. We have named this model GluA2⁺/ECS(G). By introducing a single point mutation, rather than removing the ECS entirely (as was done in prior models [37–39]), we aimed to generate a model with a more subtle phenotype that was amenable to long-term phenotyping. We herein report that these mice have reduced GluA2 Q/R site RNA editing and provide initial anatomical, behavioural, electrophysiological and seizure phenotyping, with a focus on the hippocampus. We suggest that the mice will be of value to the field for future studies investigating the role of unedited GluA2(Q) in physiology and disease.

**Materials and methods**

**Generation of mice**

A targeting construct, including exons 9–12 of the Gria2 gene, was generated from DNA cloned from a 129S6 DNA genomic library (Fig. 1a). The final construct included a single base pair guanine to cytosine mutation within the ECS which altered the endogenous ECS sequence 5′-TTTGCTGCATA-3′ to the mutated sequence 5′-TTTGCTGATA-3′. This particular nucleotide
mutation was selected as it resulted in a significantly higher proportion of unedited GluA2 RNA in an in vitro study [45]. Additionally, a neomycin gene, surrounded by loxP sites, was placed downstream of the ECS, while a thymidine kinase (TK) gene was inserted at the 3′ end of the construct. The construct was electroporated into CCE embryonic stem cells, which originate from 129SvEv mice. Colonies resistant to G418 and ganciclovir were isolated. An ES cell colony that contained the desired mutant allele was identified. This ES cell colony was electroporated with a Cre-expressing plasmid and re-plated in the absence of G418 and ganciclovir, thus excising the neomycin and leaving a single loxP site. Resulting ES cell colonies containing the neomycin-deleted allele were chosen for blastocyst injection into C57B6 embryos. Chimeric mice were bred to 129Sv mice and offspring containing the mutant allele were subsequently maintained in a 129Sv background. Mutant mice were designated GluA2+/ECS(G). In all experiments, both heterozygous male and female mice were used and compared with wildtype (WT) littermate controls aged 8–10 weeks and experiments were performed blind to genotype. Some experiments were conducted with 36-week-old mice, as indicated in the manuscript. The same mice were used for open field, rotarod and fear conditioning, in that order. Mice used in electrophysiology experiments were behaviorally naïve.

Genotyping
PCR of genomic DNA from tail biopsies was conducted for genotyping analysis. PCR was routinely performed with oligonucleotide primers for the Gria2 wild-type allele (Forward: 5′- TGT TCT GGG GAA GTT CAA T-3′, and Reverse: 5′- TGA TAT ATT TCC CCT CTT CTC AGC -3′). For the targeted allele, a primer was designed to within the loxP sequence with Reverse: 5′- TGC CCA CAT CTA AGA TTG TTG GAC -3′). PCR product sizes for the wild-type and targeted allele were 200 bp and 250 bp, respectively.

DNA sequencing
A single-step multiplex PCR targeted at amplifying exon 11 of Gria2 was utilized for confirmation of the mutation to the ECS. (Forward: 5′- TGG CAC ACT GAG GAA TTT GA-3′ and Reverse: 5′- TCA CAA ACA CAC CCA TTT GA-3′). The PCR assay was carried out in a final volume of 50 μl containing 1 x Reaction buffer, 200 μM dNTPs, 0.5 μM of each primer, 0.01 U of Q5 Hot start High Fidelity DNA Polymerase (New England Biolabs) and 1 μl of DNA template. PCR products were purified using Qiaquick PCR purification kit (Qiagen). DNA sequencing was performed using an ABI 3130xl Genetic Analyzer (Applied Biosystems) with Big Dye 3.0 chemistry, after which sequences were edited and assembled using Finch TV (Geospiza Inc.).

RNA editing assay with sanger sequencing
Animals were anesthetized with isoflurane, brains were rapidly dissected, and the hippocampus was isolated, snap frozen (in dry ice) and stored at −80 °C until required. Total RNA was isolated using a Maxell® RSC simplyRNA Tissue Kit (Promega, Cat® AS1340) and a Maxell® RSC Instrument (Promega), according to the manufacturer’s instructions. As part of the protocol a DNAse treatment step was performed. cDNA was synthesized using SuperScript III (Invitrogen) and RNaseH (Invitrogen) in a total volume of 20 μl. Both no-reverse transcriptase and master mix controls were included to ensure no contamination or cross-contamination was present in the samples. PCR amplification was performed across the editing region of GluA2 using the cDNA template (Forward: 5′- CAGCAGATTAGGCC CCTACG -3′ and Reverse: 5′- AGCCGTGTAGGAG AGATGA -3′), amplifying a 226 bp product. PCR products were run on a 2% agarose gel and bands were excised and purified using a QIAquick Gel Extraction Kit (Qiagen), according to the manufacturer’s instructions. 20 ng of purified DNA was dried with 3.2 pmol of the forward primer. Samples were sequenced at Garvan Molecular Genomics using an ABI 3130XL Genetic Analyzer and were visualised using SnapGene Viewer. The percentage of unedited RNA was quantified by measuring the peak height of the A nucleotide at the Q/R site of GluA2 sequences relative to the peak height of the G nucleotide at this position using the formula: percentage unedited templates = (peak height A/(peak height A + peak height G)) × 100, as previously published [41, 46]. The peak heights were calculated using Image J (NIH).

BbvI RNA editing assay
Animals were anesthetized with isoflurane, brains were rapidly dissected and the hippocampus was isolated, snap frozen with isopentane and dry ice and stored at −80 °C until analysis. Total RNA was isolated using Trizol Reagent (Invitrogen) according to the manufacture’s protocol and subjected to DNAse treatment (Invitrogen). cDNA was synthesized using SuperScript III (Invitrogen) and RNaseH (Invitrogen) in a total volume of 20 μl. PCR amplification was performed across the editing region of GluA2 using the cDNA template (Forward: 5′- TGC CCA CAT CTA AGA TTG TTG GAC -3′). PCR products were run on a 1.8% agarose gel and the bands were excised and gel purified using the QIAquick Gel Extraction Kit (Qiagen), yielding 30 μl of product. The gel-purified products were digested with 1 U of BbvI enzyme (New England Biolabs) in a total volume of 20 μl for a total of six h at 37 °C. The reaction was terminated at 65 °C for 20 min. The products were run on 10% TBE gels (Invitrogen). The bands were quantified using Image J and expressed as a percentage of...
the unedited band (81 bp) divided by the unedited band (81 bp) + the edited band (68 bp).

**Kainic acid-induced seizure activity**

8–10-week-old GluA2+/ECS(G) mice and littermate controls were intraperitoneally injected with 10 mg/kg kainic acid (KA, Sigma) and were observed for 1 h following injection. This dose was insufficient to induce seizures in WT mice, but was sufficient to induce mild to moderate seizures in GluA2+/ECS(G) mice. Where stated, mice were injected immediately prior to KA administration with AP-5 (20 mg/kg; Tocris) or IEM-1460 (7.5 mg/kg; Tocris).

Seizure stage was assessed by the maximum score within a five minute window, according to a modification of the Racine scale: stage 0 - normal behaviour; stage 1 - immobility; stage 2 - rigidity, whisker twitching; stage 3 - forelimb pawing, head bobbing and tail whipping; stage 4 - intermittent rearing and falling with forelimb/jaw clonus; stage 5 - continuous rearing and falling > 30 s; stage 6 - generalized tonic-clonic seizures with whole body convulsions; stage 7 death.

**Electrophysiology**

All tissue used for electrophysiology experiments was derived from behaviourally naïve animals. Coronal CA1 slices (400 μm) were prepared using a vibratome (VT1000S; Leica Microsystems) in ice-cold artificial cerebrospinal fluid (ACSF) of composition: 126 mM NaCl, 2.5 mM KCl, 1.4 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2, 11 mM glucose and 25 mM NaHCO3. Slices were maintained (≥ 1.5 h) at 30–32°C in a submerged chamber containing carbogen equilibrated (95% O2, 5% CO2) ACSF before being individually transferred to a recording chamber (≥ 30 min prior to recording) and superfused continuously (2.5 mL/min−1) with carbogen equilibrated ACSF using a recirculation system. A glass bipolar stimulating microelectrode (2–3 MΩ; filled with ACSF) was placed in the stratum radiatum.

For patch clamp experiments, CA1 neurons were visually identified using Dott-tube optics on an upright microscope (Olympus BX51). Whole-cell voltage-clamp recordings were conducted via an Axopatch 700B patch clamp amplifier, using an internal solution of the following composition: 125 mM CsMeSO3, 10 mM CsCl, 5 mM HEPES, 0.4 mM EGTA, 4 mM NaCl, 1 mM MgCl2, 2 mM MgATP, 0.3 mM NaGTP, 3 mM QX314 and 0.1 mM spermine (pH = 7.3; osmolarity = 280–285 mOsM). Series resistance (< 25 MΩ) was compensated by 80% and continuously monitored during experiments. Liquid junction potentials of ~ 15 mV were corrected. Electrically evoked AMPA-receptor mediated excitatory postsynaptic currents (EPSCs), obtained in the presence of the GABA A-receptor blocker picrotoxin (100 μM) and the NMDAR antagonist DL-AP5 (50 μM), were elicited once per 12 s. 1-naphthyl acetyl spermine (Naspm, 50 μM) was bath applied to block Ca2+-permeable AMPARs.

For long-term potentiation (LTP) experiments, field excitatory postsynaptic potentials (fEPSPs) were recorded via a glass microelectrode (2–3 MΩ; filled with ACSF) placed in the stratum radiatum 300–400 μm from the stimulating electrode. fEPSPs were evoked every 30 s, at an intensity adjusted to produce fEPSPs with amplitudes corresponding to ~ 50% of maximal responses. After obtaining 20 min of stable baseline fEPSPs, three trains of high-frequency stimulation (HFS, 100 pulses at 100 Hz, inter-train interval of 10 s) to induce LTP, and fEPSPs were recorded for another 60 min.

**Golgi staining**

Mice were anesthetized with isoflurane and cervically dislocated. Brains were stained using the FD Rapid GolgiStain Kit (FD NeuroTechnologies) as per the manufacturer’s recommendations. To analyse dendritic morphology, Golgi-stained CA1 neurons were manually traced at 100x magnification with Neurolucida (MBF Bioscience) and total dendritic lengths were measured and quantified using Neurolucida Explorer. Scholl analysis was performed with Neurolucida Explorer to demonstrate the branching patterns of neuronal dendritic trees. Spine density was assessed by counting the number of spines in 3 branches per neuron of branch orders 2–4. All protrusions no longer than 2 μm were counted as spines if they were continuous with the dendritic shaft. The spine density was defined as the number of spines on 10 μm of dendritic length.

**Immunohistochemistry**

Immunohistochemistry was conducted as previously described [47]. Tissue was cryosectioned at 40 μm (Leica Microsystems). Free-floating sections were incubated in mouse anti-NeuN (1:500; Merck Millipore) for 72 h followed by overnight incubation in biotin-labeled chicken anti-mouse secondary antibody (1:250; Invitrogen). Immunolabeling was detected using HRP-labeled avidin-biotin complex and 3,3′-Diaminobenzidine substrate (DAB; Vector Laboratories).

**Stereology**

Design based stereology, using with Stereo Investigator 7 (MBF Bioscience), was used to estimate cell populations, as previously described [47]. Briefly, estimates were conducted on the dorsal hippocampus at the anteroposterior (AP) positions from between Bregma ~ 1.34 mm and ~ 2.3 mm. For neuronal population estimates, a minimum 20 sampling sites were sampled per section on a grid size of 84 μm x 60 μm and a counting frame size of 30 μm x 30 μm. For all
cell population estimates, a guard zone of 5 μm and a disector height of 10 μm were used. Each marker was assessed at one in every sixth section, with a total of five sections being sampled. Both the CA3 and CA1 regions of the hippocampus were sampled.

**Cobalt uptake**

Mice were sacrificed, the brain rapidly removed and coronal sections (400 μm) were cut with a vibratome (Leica Microsystems) in ice cold Krebs solution buffer containing (in mM: 125 NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose, 2 CaCl2, 1 MgCl2) bubbled with 95% O2/5% CO2. Slices were allowed to recover for 1 h in Krebs at 28 °C. Slices were transferred into a pre-stimulation solution of low-sodium, low-calcium Krebs solution containing (in mM: 50 NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose, 0.5 CaCl2, 2 MgCl2) with 0.5 μM TTX (Tocris) and 100 μM AP-5 (Tocris). Control slices were pre-treated with Krebs containing NBQX (20 μM; Tocris) or GYKI (100 μM; Sigma). Slices were stimulated with kainate (20 μM; Sigma) in the low-sodium, low-calcium Krebs solution, with the addition of CoCl2 (1.5 mM). Slices were washed in Kreb’s solution without divalent ions (in mM: 50 NaCl, 2.5 KCl, 26 NaHCO3, 1.25 NaH2PO4, 25 glucose) containing EDTA (0.5 mM) for 10 min, before being incubated in Kreb’s solution without divalent ions containing 0.12% NH4S for 5 min to precipitate intracellular Co2+. Slices were then washed with Kreb’s solution without divalent ions for 5 min and fixed in 4% paraformaldehyde overnight and equilibrated in 30% sucrose for 3 days. Sections were cut in OCT (Scigen) at 40 μm on a cryostat (Leica Microsystems) and mounted onto gelatin-coated slides (Thermo Fisher Scientific).

For silver intensification, sections were incubated in 2% Na2WO4 for 10 min and then incubated in developer solution (8 parts of AgNO3 solution: 1% Triton X-100, 7.5% CH3COOH, 30.3 mM Na-acetate, 2.94 mM AgNO3; 1 part of 5% Na2WO4; 1 part of 0.25% ascorbic acid) in the dark for 15 min and washed in 2% Na2WO4, dried, rinsed in 100% xylol, and coverslipped.

**Co-Immunoprecipitations**

Co-immunoprecipitation experiments were conducted as previously described [16, 48, 49], with modification. Mice were sacrificed, brains were rapidly dissected, and the hippocampus was isolated, frozen with dry ice and stored at −80 °C until required. Tissue was homogenized in 50 mM Tris-HCl (pH 7.4) with protease inhibitors (Sigma). Cell membranes were sedimented by centrifugation at 100,000 x g for 30 min at 4 °C. The pellet was resuspended in 750 μl of 1% Triton X-100, 50 mM Tris-HCl (pH 7.4) and 1 mM EDTA followed by incubation for 45 min at 37 °C. For co-immunoprecipitations, 3 μg of antibody (GluA1, GluA2, GluA2/3, GluA4, GluA1 + 2/3, GluA2/3 + 4 or IgG) was incubated in 50 μl (1.5 mg) of Dynabead protein A (Invitrogen) according to manufacturer’s instructions. 105 μl of sample protein was incubated with antibody-bound beads at RT for 30 min with gentle agitation. Protein was subjected to two rounds of immunoprecipitations. Bound fractions from the first round of immunoprecipitation were eluted using the provided elution buffer. LDS sample buffer and reducing agent (Invitrogen) were added to bound and unbound fraction samples followed by incubation for 10 min at 70 °C prior to SDS PAGE and immunoblotting. The following AMPAR subunit-specific antibodies were used for Western blotting: GluA1 (1:1000, Millipore), GluA2/3 (1: 1000, Millipore), GluA2 (1:1000, Millipore) and GluA3 (1: 1000, Cell Signaling). The percent of total AMPAR subunit remaining in the unbound fraction was calculated based on the standard curve created from control IgG immunoprecipitated tissue.

**Open field test**

The open field test (OFT) was conducted as previously described [47]. Briefly, mice were placed in an arena (40x40cm) enclosed with clear plexiglass walls that was situated in a large sound attenuating cubicle. Mice were placed into the center of the arena and allowed to explore the test box for 10 min, while a computer software program (Activity Monitor; Med Associates) recorded activity via photobeam detection inside the testing chambers. The total distance traveled over the course of the 10 min was recorded.

**Rotarod**

Mice were placed on the suspended beam of the rotarod facing away from the viewer for 5 min. The rotarod was started once all mice were placed on the beams and rotated at a rate of 4 rpm which increased to 40 rpm over the course of 5 min. Animals were taken off the rotarod once they fell to the catch tray below or after 5 min had elapsed. The total time spent on the beam was recorded. Animals were exposed to the test once a day for three consecutive days.

**Fear conditioning**

Contextual fear conditioning was conducted as previously described [47]. Briefly, training and testing took place in cube-shaped fear-conditioning chambers (32 x 27 x 26 cm; Med Associates Inc.) that had a clear plexiglass door, ceiling and rear wall and grey aluminum side walls. Each chamber had a removable grid floor, which consisted of 36 parallel rods spaced 8 mm apart. Positioned under the grid was a removable aluminum tray for collection of waste. The rods were connected to a shock generating and scrambling system, which delivered a current to elicit a foot shock. This
system was connected to and controlled by computer software (FreezeFrame2, Actimetrics). A video camera, which was positioned in front of the chambers, recorded the behavior of the mice during training and testing. On the conditioning day, mice were placed into a fear-conditioning chamber in which the environment (context) was controlled. Mice were allowed time (3 min) to explore the context freely, prior to receiving a single moderate footshock (0.5 mA, 2 s). Following shock, all mice remained in the chamber for 30 s and were then immediately returned to their homecages. The following day, the mice were re-exposed to the same context and behavior was recorded for 3 min. Freezing was assessed as a measure of fear on all days using a 4 s sampling method by investigators, who were blind to the genotype. The number of observed freezes was averaged and divided by the total number of samples taken to yield a percentage of freezing. Data is presented as the average percentage of freezing during the 3 min period prior to shock delivery on conditioning day and during the 3 min test period on testing day.

Statistics
All statistical analysis was performed using GraphPad Prism Version 7.0 (GraphPad Software, Inc). For seizure analysis, scores were square root transformed to produce a normal distribution. Data sets were tested for outliers using a Grubbs’ test. Differences between means were assessed, as appropriate, by t-tests or one/two-way ANOVAs (with or without repeated measures, followed by Bonferroni post-hoc analysis). Where repeated measures ANOVAs were performed, we used the Geisser-Greenhouse correction (i.e. did not assume sphericity). For t-tests, data sets were first tested for normality (the D’Agostino & Pearson test where possible, or the Shapiro-Wilk test if n’s were too small for the D’Agostino & Pearson test), before using either parametric or non-parametric tests, as appropriate. For parametric tests, an F test for variance, calculated in GraphPad Prism Version 7.0, was used to determine whether standard deviations were equal between groups. If they were unequal, Welch’s correction was applied to the t test. For non-parametric tests, the Mann-Whitney test was used. Statistical significance was defined at p < 0.05 and presented as *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. Results are displayed as mean ± standard deviation, unless otherwise indicated.

Results
GluA2+/ECS(G) have ~ 20% unedited GluA2(Q) RNA
A prior in vitro study identified several key residues in the intronic ECS that are necessary for maintaining the efficiency of GluA2 pre-mRNA Q/R site editing [45]. In particular, when mutating a cytosine sitting within the ECS of intron 11 to a guanine (see mutant B13M3 in [45]), Higuchi et al., found <1% of GluA2 transcripts were edited. Building off this observation, we designed a transgenic mouse in which the ECS was altered from the endogenous sequence 5′-TTGCTGCGATA-3′ (Fig. 1a(i)), to the sequence 5′-TTGCTGGATA-3′.

Mice expressing the final mutant allele termed GluA2+/ECS(G) (Fig. 1a(iii)) were maintained as heterozygotes. Homozygote mutants were not viable. DNA sequencing confirmed a guanine residue (G) in the ECS of heterozygous GluA2+/ECS(G) mice, in the position a cytosine (C) residue would otherwise occur in the WT allele (Fig. 1b). DNA sequencing confirmed no alteration to the Q/R site in the DNA of WT and GluA2+/ECS(G) mice (Additional file 1a). Heterozygous mice were identified by PCR of the downstream in-tronic loxP sequence (Fig. 1c).

By sequencing mRNA transcripts, we determined the efficiency of GluA2 RNA editing at the Q/R site (Fig. 1d-e). We found 2.95 ± 0.48% of GluA2 is un-edited at the Q/R site in the hippocampus of WT mice (Fig. 1d). In contrast, GluA2+/ECS(G) mice showed a significant increase in proportion of un-edited GluA2(Q) RNA (20.3 ± 1.0% of total GluA2 transcripts) in the hippocampus (Fig. 1d; mean ± SD, p = 0.0079 (Mann-Whitney test)), confirming the critical importance of the ECS sequence for regulating normal GluA2 RNA editing in vivo. Editing assays conducted via Sanger sequencing may yield higher than expected editing rates in WT mice (editing rates at the Q/R site of GluA2 are thought to be > 99% in the adult brain [50]). Using a separate cohort of GluA2+/ECS(G) mice we therefore conducted a second RNA editing assessment using a standard BbvI restriction enzyme-based assay. This assay confirmed the significant increase in the proportion of unedited GluA2(Q) RNA transcripts in GluA2+/ECS(G) mice (Additional file 1b-d). Q/R site RNA alterations were confirmed via RNA sequencing in WT and GluA2+/ECS(G) mice (Fig. 1e and Additional file 1a). We also found the editing changes did not appear to grossly affect AMPAR subunit assembly (Additional file 2).

GluA2+/ECS(G) have decreased body weight, premature mortality and increased seizure susceptibility that is NMDA receptor independent
Mice with reduced GluA2 Q/R site RNA editing have previously been shown to exhibit decreased body weight [38] and premature mortality, compared with WT littermates [37, 38]. In this study, we found that GluA2+/ECS(G) mice were outwardly normal at birth, though they exhibited significant reductions in body weight at 8 weeks of age (Fig. 2a; mean ± SD, t = 3.239, df = 15, p = 0.0046 (unpaired t-test)). A
Kaplan-Meir survival curve (170 GluA2+/ECS(G) and 42 WT littermates) revealed GluA2+/ECS(G) mice were significantly susceptible to premature death as compared to WT littermates (Fig. 2b; $\chi^2 = 77.07$, df = 1, $p < 0.0001$), with a median survival of 9 weeks. Premature mortality in GluA2+/ECS(G) mice was possibly due to spontaneous seizures, which were also observed.

The extended survival of GluA2+/ECS(G), in comparison to previous mice with similar or greater GluA2 Q/R editing deficits [37, 38] allowed for an assessment of seizure susceptibility in this model and, in particular, whether seizure vulnerability is NMDAR-dependent. We injected the excitotoxin, kainic acid (KA), or KA plus the Ca$^{2+}$-permeable AMPAR antagonist, IEM-1460, intraperitoneally in GluA2+/ECS(G) and WT mice. GluA2+/ECS(G) mice exhibited significant seizure activity following a relatively low dose of KA (10 mg/kg), indicating enhanced neuronal excitability in these mice (Fig. 2c; interaction $F_{(6.708)} = 4.097$, $p < 0.0001$, genotype and treatment $F_{(5.59)} = 10.03$, $p < 0.0001$, time $F_{(5.39, 319.3)} = 43.22$, $p < 0.0001$ (repeated measures two-way ANOVA of square root transformed seizure scores,

---

**Fig. 1** Generation of GluA2+/ECS(G) mice and GluA2 Q/R site editing efficiency analysis. a Schematic representation of the i) GluA2 WT allele, ii) targeted GluA2+/ECS(G)neo allele and iii) the targeted GluA2+/ECS(G) allele, after the removal of the floxed neo cassette by Cre-mediated recombination. Exons 10, 11 and 12 are shown (black boxes). Black arrows indicate loxP sites. The position of the cytosine to guanine mutation within the ECS is indicated in red. White arrows indicate primer sets used for genotype analysis. b DNA sequencing of WT and GluA2+/ECS(G) mice confirmed the single cytosine to guanine mutation in the ECS of heterozygous mice, as highlighted in yellow. c Genotype analysis of WT and GluA2+/ECS(G) mice by PCR shows a band at 200 bp in WT and two bands at 200 bp and 250 bp in heterozygous mice. d GluA2+/ECS(G) mice exhibit a significant increase in the proportion of unedited GluA2(Q) ($n = 5$/genotype; Mann-Whitney t-test). e Representative image of sequences from WT and GluA2+/ECS(G) mice. The red arrow indicates the increased presence of A nucleotide indicating unedited RNA at the Q/R site of GluA2.
followed by Bonferroni post-hoc analysis). Furthermore, GluA2+/ECS(G) mice injected with IEM-1460, a specific inhibitor of Ca\textsuperscript{2+}-permeable AMPARs (that are either GluA2 lacking, or containing unedited Q/R site GluA2 [51]), exhibited reduced seizure behaviour that did not significantly differ from WT mice \((p > 0.05)\). In contrast, injection of the NMDAR-antagonist, AP5, did not reduce seizure vulnerability. Remarkably, the observed seizures in GluA2+/ECS(G) therefore appear to be NMDAR-independent. Combined, these results suggest that seizure susceptibility is due to the activation of Ca\textsuperscript{2+}-permeable AMPARs in GluA2+/ECS(G) mice.

GluA2+/ECS(G) have inwardly rectifying currents and enhanced LTP which is AMPAR-dependent

Ca\textsuperscript{2+}-permeable AMPARs show inwardly rectifying current/voltage (I/V) relationships [52, 53]. We therefore sought to establish whether GluA2+/ECS(G) mice exhibited this phenotype. Previous mouse models with reduced Q/R site RNA editing have illustrated altered AMPAR hippocampal CA1 current rectification and calcium permeability [37, 38]. It has generally been thought this is due to a reduction in the availability of edited GluA2, or of total GluA2 expression (i.e. an increased proportion of GluA2 lacking, Ca\textsuperscript{2+} permeable

**Fig. 2** Body weight, survival curve and seizure susceptibility analysis of GluA2+/ECS(G) mice. a GluA2+/ECS(G) mice exhibit reduced body weight, as compared to WT littermates at 8 weeks of age \((n = 6\text{ GluA2+/ECS(G)}, 11\text{ WT};\text{ unpaired t-test})\). b GluA2+/ECS(G) mice exhibit premature death and an approximate median survival age of 9 weeks \((n = 42\text{ WT}, 170\text{ GluA2+/ECS(G)};\text{ Kaplan-Meier survival analysis})\). c GluA2+/ECS(G) mice exhibit increased seizures following low-dose \((10\text{ mg/kg})\) of intraperitoneal KA injection that is blocked by the Ca\textsuperscript{2+}-permeable AMPAR antagonist, IEM-1460 though not by AP5 \((n = 16\text{ WT}, 17\text{ GluA2+/ECS(G)}, 7\text{ WT+IEM-1460}, 11\text{ GluA2+/ECS(G)+IEM-1460}, 3\text{ WT+AP5}, 11\text{ GluA2+/ECS(G)+AP5};\text{ Repeated measures ANOVA})\). Data in a represent mean ± SD and in c represent mean ± SEM. * = compared to WT, # = compared with GluA2+/ECS(G), ^ = compared with WT + IEM-1460, □ = compared with WT + AP5. One symbol, \(p < 0.05\), two symbols, \(p < 0.01\), three symbols, \(p < 0.001\), four symbols, \(p < 0.0001\).
AMPARs [37, 38]). However, this could also be due to an increase in the proportion of AMPARs containing unedited GluA2.

In the presence of AP5 (50 μM), AMPAR-mediated EPSCs were readily evoked at −70, 0 and +40 mV in CA1 neurons from both WT and GluA2+/ECS(G) mice (Fig. 3a and b). While the evoked EPSCs displayed a linear I-V relationship in WT mice, the evoked EPSC I-V relationship displayed inward rectification in GluA2+/ECS(G) mice (Fig. 3a and b). Thus, the normalized evoked EPSC amplitude at +40 mV was less in GluA2+/ECS(G) compared to WT mice (Fig. 3b; interaction F(2,46) = 18.7, p < 0.0001, genotype F(1,23) = 13.7, p = 0.0012, voltage F(2,46) = 878, p < 0.0001). In addition, AMPAR-mediated evoked EPSCs in GluA2+/ECS(G) mice were not present in WT mice, were sensitive to NASPM, a synthetic analogue of Joro spider toxin, which selectively blocks Ca2+-permeable AMPARs (Fig. 3c). On average, NASPM (50 μM) inhibited evoked EPSC amplitude by 41 ± 3% in GluA2+/ECS(G) mice, which significantly differed to the 5 ± 4% inhibition observed in WT littermates (Fig. 3c and d; p < 0.01).

GluA2-lacking AMPARs are also known to contribute to NMDA receptor-independent LTP, particularly in the CA1 region of the hippocampus [54, 55]. Whether unedited GluA2(Q)-containing AMPARs contribute to NMDA receptor-independent LTP is unknown. High frequency stimulation (HFS) successfully induced LTP in the CA1 region of both GluA2+/ECS(G) mice (180 ± 11% of baseline, p < 0.05) and WT mice (123 ± 5% of baseline, p < 0.05), but the magnitude of LTP was greater in the GluA2+/ECS(G) mice (p < 0.001; Fig. 3d). To determine the contribution of Ca2+-permeable AMPARs to LTP, LTP experiments were also performed in slices pre-incubated in the NMDA receptor antagonist DL-AP5 (100 μM). Under these conditions, HFS induced LTP in the CA1 region of both GluA2+/ECS(G) mice (144 ± 8% of baseline, p < 0.01), but not WT mice (93 ± 6% of baseline, p > 0.05; Fig. 3e). When slices were then pre-incubated in both AP5 (100 μM) and the Ca2+-permeable AMPAR antagonist IEM-1460 (50 μM), HFS did not induce LTP in the CA1 region of either GluA2+/ECS(G) mice (96 ± 9% of baseline), or WT mice (105 ± 7% of baseline; Fig. 3f). These results suggest the NMDA receptor-independent LTP observed in GluA2+/ECS(G) mice in the presence of AP5 is dependent on Ca2+-permeable AMPARs. This observation is interesting in the context of our earlier observation that GluA2+/ECS(G) mice are vulnerable to NMDAR-independent seizures (Fig. 2c).

Next, we utilised Cobalt (Co2+) labelling to directly visualize the presence of Ca2+-permeable AMPARs in WT and GluA2+/ECS(G) mice, similar to previous reports [56]. Acute hippocampal slices were stained by kainate in the presence of AP5 and TTX. Sparse Co2+ staining was observed in the CA3 hippocampal region of both GluA2+/ECS(G) and WT mice (Fig. 3g), presumably in interneurons that are known to express Ca2+-permeable AMPARs [57, 58]. In contrast, GluA2+/ECS(G) mice showed enhanced Co2+ staining compared to WTs in the CA1 hippocampal region (Fig. 3g). Collectively, these results indicate CA1 neurons exhibit a larger influx of Ca2+ (and Co2+) than CA3 neurons in GluA2+/ECS(G) mutant mice. To confirm the influx of Co2+ was AMPAR mediated, we illustrated that there was little Co2+ flux in WT hippocampal slices incubated with AMPAR antagonists NBQX and GYKI, or from GluA2+/ECS(G) mutant hippocampal slices incubated with NBQX, GYKI and Ca2+-permeable AMPAR antagonist JSTX (Fig. 3h).

Combined, the results presented in Fig. 3 indicate the increased presence of Ca2+-permeable AMPARs in GluA2+/ECS(G) mice. The Co2+ labelling assay suggests the increased presence of Ca2+-permeable receptors is specific to the CA1 region, mirroring the regional specificity of neuron loss in GluA2+/ECS(G) (see Fig. 4b and Additional file 3a). Given subunit assembly does not appear to have been grossly altered in GluA2+/ECS(G) mice (Additional file 2) we suggest the Ca2+-permeability of AMPARs in GluA2+/ECS(G) mice is possibly a direct effect of increased unedited GluA2(Q).

GluA2+/ECS(G) mice have reduced dendritic density, lower numbers of spines and hippocampal CA1, but not CA3, neuron loss

Importantly, Brusa et al., reported neurodegeneration in the CA3 of juvenile (P20) mice with Q/R site GluA2 editing deficits [37]. Additionally, Feldmeyer et al., reported a reduction in CA3 pyramidal cell dendritic length in P16 mice with reductions in GluA2 Q/R site editing [38]. However, a quantification of synapse, neuronal or glial cell numbers has not yet been conducted on tissue derived from young-adult, or adult mice with genetically reduced levels of GluA2 Q/R site RNA editing. We therefore quantified both CA1 and CA3 neuronal, microglial and astrocyte numbers in young-adult (8–10-week-old) GluA2+/ECS(G) mice. Furthermore, we analysed both dendritic length and/or spine density, specifically in CA1 neurons.

To quantify hippocampal neurons, we used design-based stereology to determine if NeuN+ cell populations were altered in the CA1 and CA3 of GluA2+/ECS(G) mice compared to WT controls (Fig. 4a and b). Intriguingly, we found no differences in NeuN+ numbers in the CA3 of WT vs. GluA2+/ECS(G) mice (Fig. 4b; mean ± SD, t = 0.24, df = 8, p = 0.82 (unpaired t-test)). In contrast, we observed a strong trend toward cell loss in the CA1 region of GluA2+/ECS(G) mice compared to WT littermates at 8-10 weeks (Fig. 4b; mean ± SD, t = 2.3, df = 8, p = 0.0507 (unpaired t-test)). In a cohort of GluA2+/ECS(G) mice surviving to 36 weeks we corroborated the CA1 neuron-
Fig. 3 (See legend on next page.)
loss specificity at 8-10 weeks by measuring NeuN+ cell numbers in the CA1 and CA3, finding significant cell loss in the CA1 (Additional file 3a; mean ± SD, t = 5.5, df = 4, p = 0.0055 (unpaired t-test)). Considering the prior report from Brusa et al., of CA3 damage, the CA1 specificity of neuron loss was unexpected.

Next, we quantified total numbers of IBA1+ microglia and GFAP+ astrocytes in 8-10-week-old mice, finding no significant differences in the numbers of either microglia located within the CA1 or CA3 neuronal cell layer (Fig. 4c; CA1, t = 0.0203, df = 4, p = 0.9848 (unpaired t-test), CA3, t = 0.8233, df = 4, p = 0.5134 (unpaired t-test)) or astrocytes located within the CA1 or CA3 cell layer (Fig. 4d; CA1, t = 0.2831, df = 4, p = 0.7912 (unpaired t-test), CA3, t = 0.7163, df = 4, p = 0.5134 (unpaired t-test)) in GluA2+/ECS(G) mice compared to WT controls.

Finally, we analysed dendritic length by Sholl analysis of golgi-stained CA1 neurons. We measured this specifically in hippocampal pyramidal CA1 neurons due to the neuron loss in this region (Fig. 4e). Analysis of the main effects indicated there was an overall significant reduction in the number of dendritic branching points at differing lengths from the neuronal soma in GluA2+/ECS(G) mice compared to WTs (Fig. 4e; interaction F (35, 576) = 1.341, p = 0.093, genotype F (1, 576) = 25.22, p < 0.0001, distance from soma, F (35, 576) = 62.76, p < 0.0001 (two-way ANOVA)). Bonferroni post-hoc analysis did not reveal any significant differences at individual branch points between the groups. In addition, there was a significant reduction of spine density on CA1 neurons from GluA2+/ECS(G) mice, compared to WT littermates (Fig. 4f; t = 4.1, df = 43, p = 0.0002 (unpaired t-test)). Collectively, these results suggest a reduction in GluA2 Q/R site RNA editing leads to hippocampal CA1, but not CA3 neuron loss. The neuron loss does not appear to be associated with a change in the total numbers of microglia and astrocytes at 8-10 weeks, however we note there are many further assessments possible for determining if alterations in microglia and astrocytes may be apparent and possibly contributing to the phenotype of GluA2+/ECS(G) mice, beyond simple cell counts. Furthermore, a GluA2 Q/R site RNA editing deficit appears to lead to a reduction in both the number of dendritic branching points and the total number of spines in CA1 hippocampal pyramidal neurons in vivo.

GluA2+/ECS(G) have impaired motor function and deficits in fear memory

Although mice with genetically reduced GluA2 Q/R site RNA editing have survived to adulthood in prior studies (with the caveat the average survival is still dramatically reduced [38, 39]), these studies have conducted only brief assessments of motor and cognitive consequences of editing deficits, including open-field behaviour [38] and spatial memory assessments [59] (although the mice in [59] also had a GluA1 KO alongside a GluA2 Q/R site editing deficit). Thus, we assessed exploratory behaviour (open-field test), motor coordination (rotarod) and hippocampal-specific memory (context fear conditioning) of 8-10-week-old GluA2+/ECS(G) mice, compared with WT littermates.

In the OFT, GluA2+/ECS(G) mice exhibited a significant reduction in total distance travelled, compared with WT controls (Fig. 5a; mean ± SD, t = 4.12, df = 16, p = 0.0008 (unpaired t-test)), indicating reduced exploratory behaviour. Furthermore, we observed impaired motor performance in GluA2+/ECS(G) mice, as evidenced by poor performance on the rotarod. Rotarod data from one mouse was removed from the WT group after being identified as a significant outlier using Grubbs’ test. There was both a significant genotype and trial effect, indicating differences between GluA2+/ECS(G) and WT mice that were altered with subsequent trials (Fig. 5b; interaction F(2, 32) = 1.69, p = 0.2011, genotype F(1, 16) = 8.86, p = 0.0090, trial F(1, 29.6) = 5.38, p = 0.0117 (repeated measures two-way ANOVA with Geisser- Greenhouse correction)).

Next, we assessed hippocampal-specific memory in GluA2+/ECS(G) mice. We conditioned both GluA2+/ECS(G) and WT mice in a context fear conditioning paradigm (pre-Shock and shock, Fig. 5c). 24 h later (Test, Fig. 5c),
we re-exposed them to the conditioning context for 3 min in the absence of shock. The magnitude of ‘freezing’ was measured both pre-shock (on Day 1) and during the test (on Day 2) to measure baseline and conditioned fear, respectively. A significant interaction and main effects of both genotype and test session occurred, suggesting that both genotype and test session affected fear, and that the former influenced the latter (Fig. 5c; interaction $F(1,28) = 59.45$, $p < 0.0001$, genotype $F(1,28) = 59.93$, $p < 0.0001$, trial $F(1,28) = 63.79$, $p < 0.0001$ (two-way ANOVA)). Bonferroni post-hoc analysis revealed no significant differences in pre-shock freezing between genotypes, suggesting no baseline fear alterations in mutant mice. However, during test day, Bonferroni post-hoc analysis illustrated WT mice display significantly more freezing than GluA2+/ECS(G) mice ($p < 0.0001$). Furthermore, pre-shock and test freezing did not differ significantly in GluA2+/ECS(G) mice suggesting...
Combined, our results reveal severe hippocampal memory deficits and motor coordination in mice that express unedited GluA2 at the Q/R site.

**Discussion**

In the present study, we report a new mouse line, called GluA2+/ECS(G), with only a single point mutation in the ECS site on intron 11 of the Gria2 gene. These GluA2+/ECS(G) mice have reduced GluA2 Q/R site RNA editing, inward rectifying AMPAR currents and altered AMPAR Ca2+-permeability, as predicted. They also appear to show grossly normal AMPAR subunit assembly. Meanwhile, the phenotype we observed in the GluA2+/ECS(G) mice was, in general, less severe than that observed in previous models [37, 38]. We discuss our initial observations in these mice below and note that they remain available for future study.

GluA2+/ECS(G) mice have a GluA2 Q/R site editing deficiency and longer lifespans than previously published models with editing impairments

Three seminal publications have previously characterised genetically modified mice with reduced Q/R
site GluA2 RNA editing [37–39]. First, Brusa et al., created a GluA2 Q/R site editing dysfunction by replacing the editing complementary sequence (ECS) and some surrounding DNA within intron 11 of the GluA2 gene (Gria2) with a single loxP site [37]. This resulted in mice with ~20% of unedited mature cytoplasmic GluA2 mRNA (see [37] for details). Second, Feldmeyer et al., generated several more GM mice with variable levels of editing (98%, ~27.8 and 8.7% unedited [38]). In the same publication they also described a transgenic mouse carrying multiple copies of a GluA2 minigene (in addition to endogenous Gria2 alleles and being expressed in a similar pattern to the endogenous protein) which encoded an asparagine (N) at the Q/R site. Third, Krestel et al., expressed a mutant from Feldmeyer et al., but controlled the expression of this mutation temporally and regionally [39]. In that study, large increases in unedited GluA2(Q) expression were restricted to the forebrain, hippocampal CA1 and dentate gyrus (DG) cells, and could be induced postnatally.

In both Brusa et al., and Feldmeyer et al., the mice generally had dramatically reduced lifespans (~P21) and were prone to spontaneous seizures. In Krestel et al., despite restricting unedited GluA2(Q) expression to postnatal periods, these mice still displayed a high mortality rate (albeit extended compared to constitutive models [38]), with ~60% dying from seizures at P60 (~8.5 weeks). In contrast to mice created by Brusa et al., and Feldmeyer et al., our constitutive mutant editing deficient mouse exhibited extended survival (although shortened compared with WT mice), with ~50% mortality by the age of 9 weeks, but are similarly prone to spontaneous seizures. The mortality rates therefore appear more akin to the model described by Krestel et al. Curiously, the mice from Krestel et al., with forebrain unedited GluA2(Q) expression (restricted to postnatal periods), exhibit a spontaneous seizure phenotype and premature mortality [39], which may suggest seizures are not solely resulting from developmentally generated effects in the various constitutively unedited GluA2 mice.

**GluA2+/ECS(G) mice exhibit altered I/V relations and NMDA receptor independent LTP, concomitant with NMDAR-independent seizure susceptibility**

As expected, through the demonstration of inward rectifying current (I/V) relationships, we identified the presence of Ca2+-permeable AMPARs in the CA1 hippocampal region of GluA2+/ECS(G) mice. Our findings are reminiscent of those from previous GluA2 Q/R site editing deficient mouse models [37–39]. The presence of Ca2+-permeable AMPARs was further confirmed using Naspm (a selective inhibitor of Ca2+-permeable AMPARs). We also demonstrated enhanced LTP in GluA2+/ECS(G) mice that was NMDAR-independent. Thus, Ca2+-permeable AMPARs, containing unedited GluA2(Q), might activate pathways normally activated by NMDARs, leading to increased neuronal excitability.

Our results also demonstrate an enhanced KA-induced seizure susceptibility in GluA2+/ECS(G) mice which, as assessed using NMDAR and AMPAR specific inhibitors, can be largely NMDAR-independent. To the best of our knowledge, susceptibility to status epilepticus, induced by KA, has not previously been assessed in mice with constitutively impaired GluA2 Q/R editing. Importantly, AP5, an NMDAR antagonist, has previously been illustrated to have effects in the CNS of rats and mice, when administered peripherally, at equivalent doses to that used here [60–69]. This suggests it is unlikely any lack of effect of AP5 was caused by poor penetration into the brain. Furthermore, we [55] and others [70–72] have previously found CNS effects after peripheral administration of the AMPAR antagonist IEM-1460. We note that it is possible our results may be partially explained by IEM-1460 penetrating the brain more efficiently than AP5. This will be important to rule out in future work.

The results we observed are generally different to those observed in GluA2 knockout or knockdown mice. Hippocampal knockdown of GluA2 in age P13 rats [73], but not adult rats [73, 74] (or adult mice, as we have previously illustrated [55]), leads to an enhanced seizure phenotype in the presence of KA, supporting the concept GluA2 downregulation contributes to seizures in young, but not adult, animals [73]. Meanwhile, intriguingly, GluA2 KO mice have less frequent absence seizures in response to γ-Hydroxybutyric acid than controls [75].

Perhaps most intriguingly, our finding that GluA2+/ECS(G) mice have NMDAR-independent seizures, that are instead dependent on Ca2+-permeable AMPARs, may have important clinical implications. Altered RNA editing has been implicated in the aetiology of seizures [76]. Meanwhile, NMDAR antagonists have had mixed results in treating seizures in humans, though they are proposed as second line therapy for status epilepticus [77]. The effect of seizures on GluA2 RNA editing has not been extensively studied and our results suggest the efficacy of NMDAR antagonists may be limited if RNA editing is reduced. Our study provides an imperative to further assess the concept that Ca2+-permeable AMPARs, particularly those containing unedited GluA2(Q) subunits, could provide a novel target for seizure control in patients [78, 79].

**GluA2+/ECS(G) mice have CA1 specific neuron loss and CA1 synapse loss**

We found neuronal death was specific to the CA1 hippocampal region, with no evidence of degeneration in the
CA3 region in adult GluA2+/ECS(G) mice, including in an aged cohort (Additional file 3). The selectivity of the degeneration seems consistent with, and may be explained by, our Cobalt (Co²⁺) labelling results, which suggested a greater concentration of AMPAR-dependent Ca²⁺-permeable cells in the CA1 compared to the CA3 region, a finding that remains open for future investigation.

Our findings contrast to those illustrating dendritic length reduction [38] and cellular [37, 38] degeneration in the CA3 region of previous editing mutant mice and from studies showing a lack of hippocampal degeneration in adult rats following either ADAR2 gene silencing [34], which reduces Q/R site GluA2 editing, or after overexpression of unedited GluA2(Q) in adults [43, 44].

Our results also contrast with a report that unedited GluA2(Q) induces spine growth in pyramidal cells and interneurons in vitro [80], since we found spine and dendritic loss in adult GluA2+/ECS(G) mice. We cannot explain why our findings are different, but it may reflect differences in study design, particularly that our study was in vivo. It is also not yet clear why GluA2+/ECS(G) mice have CA1, but not CA3 neuron loss. CA3 injury and basal dendrite length reductions were previously observed in the young (<P20) GluA2 Q/R site editing mutant mice that had prolonged seizure episode and shorter lifespans than GluA2+/ECS(G) mice [37, 38]. Thus, CA3 damage could be explained by the severe seizure phenotype observed in these models. We also note these prior studies did not perform stereological cell counting, as performed in this study and that the design of the mutant mice differs in that these prior models had complete removal of the ECS.

The regional sensitivity to unedited GluA2(Q) could be explained by the higher expression of GluA2 and AMPARs in the CA1, compared with the CA3 and DG [81, 82] and, as suggested above, it is consistent with the finding of greater cobalt staining in the CA1 versus CA3 region. Our finding of CA1 neuron loss is also consistent with studies illustrating unedited GluA2(Q) expression can reduce the threshold for CA1 damage following an acute insult, such as ischemia [34, 43, 44]. In summary, although we cannot completely explain the CA1, but not CA3 neurodegeneration in GluA2+/ECS(G) mice, it is reasonable to consider that increased levels of unedited GluA2(Q) may differentially affect these populations, particularly in the absence of neurotoxic insults.

**GluA2+/ECS(G) mice have impaired motor function and deficits in fear memory**

GluA2+/ECS(G) mice exhibited deficits in open field behaviour. The impairment was possibly driven by a reduction in motor coordination, as exhibited by a reduced ability to perform the rotarod task. The observation of motor deficits in GluA2+/ECS(G) mice was not wholly unexpected, not only due to these deficits previously being reported in GluA2 Q/R site editing deficient mice [38] (including in GluA2 KO mice, which also have motor neuron degeneration [83, 84]), but also because of well-established evidence of GluA2 Q/R site editing deficiencies in the spinal motor neurons of sporadic ALS patients [85]. Any future work would benefit from a thorough characterisation of motor deficits, or assessments of motor neuron cell numbers in GluA2+/ECS(G) mice.

The hippocampal fear memory deficit we observed, using the hippocampal-dependent context fear conditioning paradigm, is likely the result of hippocampal synaptic plasticity deficits (Fig. 3), CA1 spine and neuron loss (Fig. 4), or a combination of both. In the context of studies implicating GluA2 Q/R site editing deficits in AD [29, 30], our results provide some evidence to suggest alterations in the proportion of GluA2 Q/R may be capable of aetiologically driving hippocampal learning and memory deficits in dementia, if present in neurons of affected individuals.

We note that GluA2 KO mice have reduced motor coordination on the rotarod [54] and GluA2 lacking receptors can play a role in LTP [54, 86] and NMDAR-independent hippocampal-specific learning [55]. However, we have only undertaken preliminary characterisations of the GluA2+/ECS(G) mice in this study and much more detailed assessments may be valuable in future to tease out the phenotypic differences from GluA2 KOs.

**Limitations**

We cannot categorically state, nor do we rule out, that the phenotype of GluA2+/ECS(G) mice may be partially explained by Ca²⁺-signalling through GluA2-lacking AMPARs. However, we consider it unlikely: homomeric unedited GluA2(Q) receptors are known to be delivered to synapses ex vivo [44], recombinant unedited GluA2(Q) containing AMPARs rapidly replace native AMPARs [87], GluA2(Q) homomers are readily trafficked to the cell surface and enable CA1 LTP [88] and unedited GluA2(Q) containing receptors are functional [18–20, 87]. Furthermore, notwithstanding our detection method may not be sensitive enough to detect small changes, GluA2+/ECS(G) mice do not show gross alterations in AMPAR subunit assembly (Additional file 2), in contrast to GluA2 KO mice [49]. We note our preliminary evidence is insufficient to draw strong conclusions, other than a lack of gross changes in receptor assembly.

Additionally, the cell loss we observe in the mice is reminiscent of the effects of unedited GluA2(Q) expression in vitro: viral-mediated expression of unedited GluA2(Q) in primary neurons renders these neurons specifically susceptible to AMPA-induced toxicity, in comparison with cells expressing GluA1 or GluA2(R) [89]. Meanwhile, we,
and others, have previously shown GluA2 knockdown or knockout does not lead to hippocampal cell loss [23, 54, 55, 74], unlike that seen in the present study (although we note contrary findings [90, 91]).

We note also that the neurodegeneration we have observed may represent a neurodevelopmental deficit induced by unedited GluA2(Q), a theory supported by findings that overexpression of unedited GluA2(Q) in adult rats does not lead to acute hippocampal neurotoxicity [34, 43, 44]. However, as noted earlier, inducible expression of unedited GluA2 in adult mice does lead to seizures [39], suggesting that the seizure vulnerability is not solely a developmental defect.

Our findings, placed in the context of prior studies illustrating unedited GluA2(Q) containing AMPARs are present at the cell surface, are functional and contribute to AMPAR signalling, make it reasonable to suggest unedited GluA2(Q) incorporation into AMPARs is contributing to the increased AMPAR Ca²⁺-permeability, enhanced NMDAR-independent LTP, CA1 specific-neuron loss and behavioural deficits in GluA2⁺/ECS(G) mice.

Conclusions and future directions

The current study provides an initial characterisation of GluA2⁺/ECS(G) mice. Unedited GluA2(Q) expression could influence GluA2 trafficking [92], maturation or AMPAR tetramerization [50]. At present, we have evidence from GluA2⁺/ECS(G) mice, provided in Additional file 2, that AMPARs may be forming and trafficking normally, but the data is an initial characterisation only. A comprehensive and sophisticated analysis of gene and protein expression of GluA2, other GluAs, and the myriad of proteins implicated in GluA2 RNA editing, trafficking and AMPAR assembly, as well as trafficking and surface expression analyses, would be of value in future work. Future investigations should also consider unedited and edited GluA2 may have unique regional and temporal effects within different populations of cells and perhaps even within the same population of cells [93, 94].

The observations in the current study provide further support to the idea [34, 84] that unedited GluA2(Q) may be a therapeutically relevant target for preventing neurodegeneration and behavioural impairments in a range of neurological conditions and, given the results of this study, NMDAR-independent seizures. This is, of course, also implied by the reduced GluA2 Q/R site editing efficiency in several neurological conditions including Alzheimer’s disease [29–31], schizophrenia [30], Huntington’s disease [30], amyotrophic lateral sclerosis [32], astrocytoma [33], stroke [34] and cocaine seeking behaviour in rats [35] and by prior observations that overexpression of ADAR2, or overexpression of edited GluA2, can provide therapeutic benefit in some models [34, 35, 84]. GluA2⁺/ECS(G) mice may therefore offer a new valuable tool for the community going forward and will be made readily available for further study.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13041-020-0545-1.

Additional file 1: (A) Q/R site DNA and mRNA sequences. DNA sequencing of the Q/R site revealed the CAG codon in both the WT and GluA2⁺/ECS(G), indicating no alteration to the site. cDNA sequencing of the site revealed the CCG codon in WT mice, and a marked increase in adenosine in GluA2⁺/ECS(G) at the CCG codon, confirming the RNA editing assay results in GluA2⁺/ECS(G) mice. (B) Schematic representation of GluA2 cDNA BbvI digestion. The restriction digest produced 2 bands for edited GluA2 (225 bp and 68 bp) and 4 bands for unedited GluA2 (225 bp, 144 bp, 81 bp and 68 bp). (C) BbvI restriction enzyme digest of PCR product from WT and GluA2⁺/ECS(G) mice cDNA. (D) BbvI digestion assay results: GluA2⁺/ECS(G) mice exhibit a significant increase in unedited GluA2 at the Q/R site (n = 3/genotype; unpaired t-test).

Additional file 2: Schematic representation of the co-immunoprecipitation assay and unbound and bound fraction data. (A) Co-immunoprecipitations were performed by utilising the Dynabead® protein A Immunoprecipitation kit. Dynabead protein A provided was allowed to bind for 20 min with gentle agitation. Following washing, protein sample was added and incubated at RT for 30 min with gentle agitation. The sample was removed via the provided magnet and the unbound fraction (round 1) was kept. The bound fraction was eluted with the provided elution buffer. The unbound fraction was subjected to another round of immunoprecipitations and subsequent to this the fraction (unbound fraction round 2) was used for SDS gel electrophoresis to identify associated AMPA subunits using the appropriate antibody. (B) AMPA receptor subunits remaining after immunoprecipitation of hippocampal homogenates from GluA2⁺/ECS(G) and WT mice (n = 3/genotype; t-test). (C) Co-immunoprecipitation bound fraction analysis revealed correct protein binding. The co-immunoprecipitation bound fraction was a result of one round of precipitation with the Protein A kit, and reveals significant binding of the appropriate protein in the respective blots. This corresponds to the absence of the respective proteins in B, and shows a correct procedure. The bound fraction cannot be quantified. This is because, as is often the case, two rounds of immunoprecipitation were required to pull down greater than 95%. Lower band represents elution of the antibody.

Additional file 3: (A) Significant cell loss in the CA1 but not CA3 region of the hippocampus in 36-week-old adult GluA2⁺/ECS(G) mice as compared to WT littermates (n = 3/genotype; unpaired t-test). (B) IBA1+ cell quantification in the CA1 and CA3 of 36-week-old GluA2⁺/ECS(G) mice as compared to WT littermates (n = 3/genotype).

Abbreviations

ACSF: Artificial cerebrospinal fluid; ADAR: Adenosine deaminase acting on RNA; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; AP: Anteroposterior; CNS: Central nervous system; DG: Dentate gyrus; ECS: Editing complementary sequence; fEPSP: Field excitatory postsynaptic potentials; HFS: High-frequency stimulation; KA: Kainic acid; LTP: Long-term potentiation; OFT: Open field test; TK: Thymidine kinase; WT: Wild-type

Acknowledgements

This paper acknowledges Stephen F. Heinemann who passed away, August 2014, with whom the study was originally initiated and who is still deeply appreciated for his mentorship and friendship to Bv and GR. The authors would like to thank members of the Biological Testing Facility for technical support and the members of the Centre of Neuroscience and Regenerative Medicine at the University of Technology, Sydney, for their resilience, support and their assistance in reading and editing this manuscript.
Authors’ contributions
Conducted experiments: AK, AW, GR, GM, BL, PS, RZ, LM, BV. Analyzed and interpreted data: AK, AW, GR, GM, BL, PS, RZ, LM, CV, BV. Drafted manuscript: AK, AW, GM, BV. All authors read and approved the final manuscript.

Funding
This work was supported by Helen and David Baffsky, Julian Segal, David King and family, Tony and Vivian Howland-Rose, Doug Batterys and family, Iain Gray in honour of Kylie, Andrew Urquhart and family, Noel Passalqua and family and Stanley and Charmaine Roth. Funding was also provided by the NHMRC (grant 1083569). The funders had no role in the planning, writing, study analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All animal experiments were carried out with the approval of the Garvan Institute of Medical Research and St Vincent’s Hospital Animal Ethics Committee under project codes 14/40 and 17/28 in accordance with the Institute of Medical Research and St Vincent Hospital Animal Ethics and Health Sciences, School of Medicine, Grafton, Auckland 1023, New Zealand. aKolling Institute of Medical Research, Royal North Shore Hospital, The University of Sydney, Sydney 2065, Australia.

Consent for publication
All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1Centre for Neuroscience and Regenerative Medicine (CNRM), Faculty of Science, University of Technology Sydney, PO Box 123 Broadway, Sydney, NSW 2007, Australia. 2St Vincent’s Centre for Applied Medical Research, Sydney 2011, Australia. 3Department of Biomedical Sciences, Faculty of Medicine & Health Sciences, Macquarie University, Sydney, New South Wales 2109, Australia. 4Middlemore Hospital, Counties Manukau DHB, Otahuhu, Auckland 1062, New Zealand. 5The University of Auckland, Faculty of Medical and Health Sciences, School of Medicine, Grafton, Auckland 1023, New Zealand. 6Kolling Institute of Medical Research, Royal North Shore Hospital, The University of Sydney, Sydney 2065, Australia.

Received: 24 September 2019 Accepted: 5 January 2020

References
1. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62(3):405–96.
2. Greger IH, Watson JF, Cull-Candy SG. Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins. Neuron. 2017;94(4):713–30.
3. Isaac JT, Ashby MC, McBain CJ. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron. 2007;54(6):859–71.
4. Lu W, Shi Y, Jackson AC, Bjorgan K, During MJ, Sprengel R, et al. Subunit composition of recombinant AMPA receptors revealed by a single-cell genetic approach. Neuron. 2009;62(2):254–68.
5. Roche JM, Milovacovic M, Wolf ME. Quantitative analysis of AMPA receptor subunit composition in addiction-related brain regions. Brain Res. 2011;1367:223–33.
6. Zhao Y, Chen S, Swensen AC, Qian W-J, Gouaux E. Architecture and subunit arrangement of native AMPA receptors elucidated by cryo-EM. Science. 2019;364(6438):355–62.
7. Roche JM, O’Brien RJ, Mannen AL, Bernhardt J, Huganir RL. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron. 1996;16(6):1179–88.
8. Hayashi T, Rumbaugh G, Huganir RL. Differential regulation of AMPA receptor subunit trafficking by palmitoylation of two distinct sites. Neuron. 2005;47(5):709–23.
9. Penn AC, Balik A, Wozny C, Cais O, Greger IH. Activity-mediated AMPA receptor remodeling, driven by alternative splicing in the ligand-binding domain. Neuron. 2012;76(3):503–10.
10. Wright A, Vissel B. The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front Mol Neurosci. 2012;5:34.
11. Eisenberg S, Levanon EY. Ato-R RNA editing — immune protector and immune suppressor. Annu Rev Biochem. 2010;79:321–49.
12. Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2005;74:591–622.
13. Perlman DJ, Inouye D, Mitrophanous K, Strambini M, van Berkel WJ, Wolf ME. Quantitative analysis of AMPA receptor subunit composition in addiction-related brain regions. Brain Res. 2019;1715:5–13.
14. Sommer B, Kohler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 1991;67(1):11–9.
15. Licht K, Hartl M, Amirian F, Arathre D, Janiszew P, Jantsch MF. Inosine induces context-dependent recoding and translational stalling. Nucleic Acids Res. 2019;47(1):3–14.
16. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci. 1996;16(6):1982–9.
17. Kuner T, Beck C, Sakmann B, Seeburg PH. Channel-lining residues of the AMPA receptor M2 segment: structural environment of the Q/R site and identification of the selectivity filter. J Neurosci. 2001;21(12):4162–72.
18. Verdoorn TA, Bumaseh N, Monyer H, Seeburg PH, Sakmann B. Structural determinants of ion flow through recombinant glutamate receptor channels. Science. 1991;252(5013):715–8.
19. Hume R, Dingledine R, Heinemann S. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science. 1991;253(5023):1028–31.
20. Bumaseh N, Monyer H, Seeburg PH, Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron. 1992;8(1):189–98.
21. Swanson GT, Kamboj SK, Cull-Candy SG. Single-Channel properties of recombinant AMPA receptors depend on RNA editing, splice variation, and subunit composition. J Neurosci. 1997;17(1):58–69.
22. Hollmann M, Hartley M, Heinemann S. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science. 1991;252(5007):851–3.
23. Kark K, Zamarillo D, Rozov A, Bumaseh N, Sprengel R, Seeburg PH. The AMPA receptor subunit GluR-B in its Q/R site-unedited form is not essential for brain development and function. Proc Natl Acad Sci U S A. 1998;95(23):13777–82.
24. Penn AC, Balik A, Greger IH. Steric antisense inhibition of AMPA receptor Q/R editing reveals tight coupling to intronic editing sites and splicing. Nucleic Acids Res. 2012;41(2):1113–23.
25. Whitney NP, Peng H, Erdmann NB, Tian C, Monaghan DT, Zeng X. Calcium-permeable AMPA receptor subunits containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons. FASEB J. 2008;22(8):2888–900.
26. Slavov D, Gardner K. Phylogenetic comparison of the pre-mRNA adenosine deaminase ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing patterns. Gene. 2002;259(1–2):83–94.
27. Kung SS, Chen YC, Lin WH, Chen CC, Chow WY. Q/R RNA editing of the AMPA receptor subunit 2 (GluR2) transcript evolves no later than the appearance of cartilaginous fishes. FEBS Lett. 2002;520(2):277–81.
28. Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Bumaseh N, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6801):78–81.
29. Gaisler-Salomon I, Kravitz E, Feiler Y, Safran M, Biegon A, Amariglio N, et al. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer’s disease. Neurobiol Aging. 2014;35(8):1785–91.
30. Akbarian S, Smith MA, Jones EG. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer’s disease, Huntington’s disease and schizophrenia. Brain Res. 1995;692(1):297–304.
31. Kherms S, D’Citra AM, Barak M, Anneke A, Wachtel C, Levanon EY, et al. Reduced levels of protein editing by Ato-R RNA editing in Alzheimer’s disease. RNA. 2016;22(2):290–302.
32. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Ikawa S. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427(6977):801.
33. Maas S, Patt S, Schrey M, Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001;98(25):14687–92.
Peng PL, Zhong X, Tu W, Soundarapandan MM, Molner P, Zhu D, et al. ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron. 2006; 49(5):79–33.

Schmidt HD, McFarland KN, Darnell SB, Huizenga MN, Sangrey GR, Cha J-H, et al. ADAR2-dependent GluR2 editing regulates cocaine seeking. Mol Psychiatry. 2014;20(1):1460.

Filippini A, Bonini D, La Via L, Barbon A. The good and the bad of glutamate receptor RNA editing. Mol Neurobiol. 2017;54(6):679–805.

Brusa R, Zimmermann F, Koh D-S, Feldmeyer D, Gass P, Seeburg PH, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient <cemo>GluR-B<reno>-allelic in mice. Science. 1995;270(5242):1677–80.

Feldmeyer D, Kask K, Brusa R, Kornau HC, Kolhekar R, Rozov A, et al. Neurological dysfunctions in mice expressing different levels of the Q/R site–edited AMPAR subunit GluR-B. Nat Neurosci. 1999;2(1):57–64.

Krestel HE, Shimshek DR, Jensen V, Nevan T, Kim J, Geng Y, et al. A genetic switch for epilepsy in adult mice. J Neurosci. 2004;24(46):10568–76.

Li IC, Chen Y-C, Wang Y-F, Tseng B-W, Ou C-W, Lau Y-Y, et al. Zebrafish Adar2 edits the Q/R site of AMPA receptor Subunit gla2a2 transcript to ensure normal development of nervous system and cranial neural crest cells. PLoS One. 2014;9(5):e97133.

Daniel C, Widmark A, Rigardt D, Öhman M. Editing inducer elements increases A-to-I editing efficiency in the mammalian transcriptome. Genome Biol. 2017;18(1):195.

Horsch M, Seeburg PH, Adler T, Aguiar-Pimentel JA, Becker L, Calzada-Wack J, et al. Requirement for the RNA-editing enzyme ADAR2 for normal physiology in mice. J Biol Chem. 2011;286(21):18614–22.

Anzai T, Tsuzuki K, Yamada N, Hayashi T, Iwakuma M, Inada K, et al. Overexpression of Ca2+-permeable AMPA receptor promotes delayed cell death of hippocampal CA1 neurons following transient forebrain ischemia. Neurosci Res. 2003;46(1):41–51.

Liu S, Lau L, Wei J, Zhu D, Zou S, Sun H-S, et al. Expression of Ca2+-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neurosci. 2004;43(1):43–55.

Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH. RNA editing of AMPA receptor subunit GluR2: a base-paired intron-exon structure determines position and efficiency. Cell. 1993;75(7):1361–70.

UCHIDA H, Matsumura S, Okada T, Suzuki T, Minami T, Ito S. RNA editing enzyme ADAR2 is a mediator of neuropathic pain after peripheral nerve injury. FASEB J. 2017;31(5):1847–55.

Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One. 2013;8(4):e59586.

Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y, et al. Requirement of the RNA-editing enzyme ADAR2 for normal development of nervous system and cranial neural crest cells. PLoS One. 2014;9(5):e97133.

38. Feldmeyer D, Kask K, Brusa R, Kornau HC, Kolhekar R, Rozov A, et al. Neurological dysfunctions in mice expressing different levels of the Q/R site–edited AMPAR subunit GluR-B. Nat Neurosci. 1999;2(1):57–64.

39. Krestel HE, Shimshek DR, Jensen V, Nevan T, Kim J, Geng Y, et al. A genetic switch for epilepsy in adult mice. J Neurosci. 2004;24(46):10568–76.

40. Li IC, Chen Y-C, Wang Y-F, Tseng B-W, Ou C-W, Lau Y-Y, et al. Zebrafish Adar2 edits the Q/R site of AMPA receptor Subunit gla2a2 transcript to ensure normal development of nervous system and cranial neural crest cells. PLoS One. 2014;9(5):e97133.

41. Daniel C, Widmark A, Rigardt D, Öhman M. Editing inducer elements increases A-to-I editing efficiency in the mammalian transcriptome. Genome Biol. 2017;18(1):195.

42. Horsch M, Seeburg PH, Adler T, Aguiar-Pimentel JA, Becker L, Calzada-Wack J, et al. Requirement for the RNA-editing enzyme ADAR2 for normal physiology in mice. J Biol Chem. 2011;286(21):18614–22.

43. Anzai T, Tsuzuki K, Yamada N, Hayashi T, Iwakuma M, Inada K, et al. Overexpression of Ca2+-permeable AMPA receptor promotes delayed cell death of hippocampal CA1 neurons following transient forebrain ischemia. Neurosci Res. 2003;46(1):41–51.

44. Liu S, Lau L, Wei J, Zhu D, Zou S, Sun H-S, et al. Expression of Ca2+-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neurosci. 2004;43(1):43–55.

45. Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH. RNA editing of AMPA receptor subunit GluR2: a base-paired intron-exon structure determines position and efficiency. Cell. 1993;75(7):1361–70.

46. Uchida H, Matsumura S, Okada T, Suzuki T, Minami T, Ito S. RNA editing enzyme ADAR2 is a mediator of neuropathic pain after peripheral nerve injury. FASEB J. 2017;31(5):1847–55.

47. Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, et al. Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One. 2013;8(4):e59586.

48. Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y, et al. Requirement of the RNA-editing enzyme ADAR2 for normal development of nervous system and cranial neural crest cells. PLoS One. 2014;9(5):e97133.

49. Krestel HE, Shimshek DR, Jensen V, Nevan T, Kim J, Geng Y, et al. A genetic switch for epilepsy in adult mice. J Neurosci. 2004;24(46):10568–76.

50. Li IC, Chen Y-C, Wang Y-F, Tseng B-W, Ou C-W, Lau Y-Y, et al. Zebrafish Adar2 edits the Q/R site of AMPA receptor Subunit gla2a2 transcript to ensure normal development of nervous system and cranial neural crest cells. PLoS One. 2014;9(5):e97133.

51. Daniel C, Widmark A, Rigardt D, Öhman M. Editing inducer elements increases A-to-I editing efficiency in the mammalian transcriptome. Genome Biol. 2017;18(1):195.
81. Coultrap SJ, Nixon KM, Alvestad RM, Fernando Valenzuela C, Browning MD. Differential expression of NMDA receptor subunits and splice variants among the CA1, CA3 and dentate gyrus of the adult rat. Mol Brain Res. 2005;135(1):104–11.

82. Kristensen BW, Noraberg J, Zimmer J. Comparison of excitotoxic profiles of AITPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures. Brain Res. 2001;917(1):21–44.

83. Akamatshu M, Yamasita T, Hirose N, Teramoto S, Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6:28649.

84. Hideyama T, Yamashita T, Suzuki T, Tsuchi S, Higuchi M, Seeburg PH, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci. 2010;30(36):11917–25.

85. Yamashita T, Kwak S. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Brain Res. 2014;1584:28–38.

86. Youn DH, Royle G, Kolaj M, Vissel B, Randic M. Enhanced LTP of primary afferent neurotransmission in AMPA receptor GluR2-deficient mice. Pain. 2008;136(1–2):158–67.

87. Sudo M, Okado H, Iino M, Tsuzuki K, Miwa A, Kanegae Y, et al. Postsynaptic expression of Ca2+-permeable AMPA-type glutamate receptor channels by viral-mediated gene transfer. Mol Brain Res. 1999;65(2):176–85.

88. Granger AJ, Shi Y, Lu W, Cerpas M, Nicoll RA. LTP requires a reserve pool of glutamate receptors independent of subunit type. Nature. 2013;493(7433):495–500.

89. Mahajan SS, Ziff EB. Novel toxicity of the unedited GluR2 AMPA receptor subunit dependent on surface trafficking and increased Ca2+-permeability. Mol Cell Neurosci. 2007;35(3):470–81.

90. Oguro K, Oguro N, Kojima T, Grooms SY, Calderone A, Zheng X, et al. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by subthalal ischemia in hippocampal CA1 and CA3 neurons. J Neurosci. 1999;19(21):9218–27.

91. Tanaka H, Calderone A, Jover T, Grooms SY, Yokota H, Zukin RS, et al. Ischemic preconditioning acts upstream of GluR2 down-regulation to afford neuroprotection in the hippocampal CA1. Proc Natl Acad Sci. 2002;99(4):2362–7.

92. Greger IH, Khatri L, Ziff EB. RNA editing at Arg607 controls AMPA receptor exit from the endoplasmic reticulum. Neuron. 2002;34(5):759–72.

93. Picardi E, Horner DS, Pesole G. Single-cell transcriptomics reveals specific RNA editing signatures in the human brain. RNA. 2017;23(6):860–5.

94. Yablonovitch AL, Deng P, Jacobson D, Li JB. The evolution and adaptation of A-to-I RNA editing. PLoS Genet. 2017;13(11):e1007064.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.